Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Brenda W Cooper, Molly Megan Gallogly, Leland Metheny, Rebecca B. Klisovic, Kirsten Marie Boughan, Jane Reese Koc, Darong Wu, Changchun Deng, Koen Van Besien, Rose Tupta, Dina Schneider, Lisa Ciarrone, Marcos de Lima, Paolo F. Caimi, Benjamin K. Tomlinson

Blood (2023) 142 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2023-191153

Published: 2023

Journal Articles

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Tyce Kearl, Anthony Zamora, Jessica Neumann, Parameswaran N. Hari, Dina Schneider, Walter Longo, Peiman Hematti, Bryon D. Johnson, Mehdi Hamadani, Timothy S. Fenske

Blood (2023) 142 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2023-173954

Published: 2023

Journal Articles

A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Sumithira Vasu, Lapo Alinari, Nicole Szuminski, Dina Schneider, Nathan Denlinger, Wing Keung Chan, Khalid Parris, Nidhi Sharma, Hillary Bradbury, Beth Daneault, Lynn O'Donnell, Boro Dropulic, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 7474–7475.

https://doi.org/10.1182/blood-2022-167340

Published: 2022

Journal Articles

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Parameswaran Hari, Dina Schneider, Bryon Johnson, Mehdi Hamadani, Timothy S. Fenske

Blood (2022) 140 (Supplement 1): 9318–9319.

https://doi.org/10.1182/blood-2022-158695

Published: 2022

Journal Articles

Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tatjana Holzer, Stefanie Biedermann, Inga Herfort, Birte Friedrichs, Silke Holtkamp, Linda Hanssens, Mario Assenmacher, Ulf Bethke, Dina Schneider, Stefan Miltenyi, Toon Overstijns, Christoph Schmid, Francis A. Ayuk, Christoph Scheid, Anja Jühling, Udo Holtick, Philipp Gödel, Peter Borchmann, Iris Bürger

Blood (2022) 140 (Supplement 1): 4581–4583.

https://doi.org/10.1182/blood-2022-164597

Published: 2022

Journal Articles

8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Walter L. Longo, Parameswaran Hari, Dina Schneider, Bryon Johnson, Timothy S. Fenske, Mehdi Hamadani

Blood (2022) 140 (Supplement 1): 7480–7481.

https://doi.org/10.1182/blood-2022-169119

Published: 2022

Journal Articles

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Blood (2022) 140 (5): 451–463.

https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Andreas Mackensen, Linda Hanssens, Matthias Stelljes, Wolfgang A Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner, Alisa Yakushina, Sandra Karitzky, Silke Holtkamp, Mario Assenmacher, Marion Jurk, Georg Rauser, Dina Schneider, Claudia Rossig

Blood (2021) 138 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2021-152452

Published: 2021

Journal Articles

Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2

Joanna C. Zurko, Huiqing Xu, Katherine Chaney, Timothy S. Fenske, Mehdi Hamadani, Dina Schneider, Parameswaran Hari, Bryon Johnson, Nirav N. Shah

Blood (2021) 138 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2021-146882

Published: 2021

Journal Articles

Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose

Joanna C. Zurko, Katherine Chaney, Huiqing Xu, Dina Schneider, Parameswaran Hari, Bryon Johnson, Nirav N. Shah

Blood (2021) 138 (Supplement 1): 3883.

https://doi.org/10.1182/blood-2021-147405

Published: 2021

Journal Articles

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Joanna C. Zurko, Dina Schneider, Sharon Yim, Mehdi Hamadani, Timothy S. Fenske, Bryon Johnson, Parameswaran Hari

Blood (2021) 138 (Supplement 1): 95.

https://doi.org/10.1182/blood-2021-146638

Published: 2021

Journal Articles

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-136067

Published: 2020

Journal Articles

A Fully-Human Armored BCMA CAR Boosts Function of CD4 + CAR-T Cells and Resists TGF-β Suppression in Pre-Clinical Models of Multiple Myeloma

Leah Alabanza, PhD, Bang Vu, PhD, Darong Wu, MS, Zhongyu Zhu, PhD, Boro Dropulic, PhDMBA, Dina Schneider, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-141062

Published: 2020

Journal Articles

Fully Human Tandem CD22-CD19 CAR-T Cells with Superior Sensitivity to Low Antigen Density Derived by Optimization of Co-Stimulation and CAR Architecture

Peirong Hu, PhD, Ying Xiong, PhD, Darong Wu, MS, Zhongyu Zhu, PhD, Boro Dropulic, PhDMBA, Dina Schneider, PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140836

Published: 2020

Journal Articles

Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

Tyce Kearl, MD PhD, Ao Mei, Ryan Brown, Bryon Johnson, PhD, Dina Schneider, PhD, Boro Dropulic, PhDMBA, Parameswaran Hari, MD MRCP, Nirav N. Shah, MD, Subramaniam Malarkannan, PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142937

Published: 2020

Journal Articles

Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial

Huiqing Xu, MD, Katherine Chaney, MS, Bryon Johnson, PhD, Timothy S. Fenske, MD, Mehdi Hamadani, MD, Boro Dropulic, PhDMBA, Dina Schneider, PhD, Parameswaran Hari, MD MRCP, Nirav N. Shah, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-136805

Published: 2020

Journal Articles

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Fenlu Zhu, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Walter L. Longo, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Boro Dropulic, PhD, Rimas J Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2019) 134 (Supplement_1): 4465.

https://doi.org/10.1182/blood-2019-125328

Published: 2019

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

Journal Articles

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Blood (2019) 134 (Supplement_1): 2625.

https://doi.org/10.1182/blood-2019-130370

Published: 2019

NARROW

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2

Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Fully-Human Armored BCMA CAR Boosts Function of CD4 + CAR-T Cells and Resists TGF-β Suppression in Pre-Clinical Models of Multiple Myeloma

Fully Human Tandem CD22-CD19 CAR-T Cells with Superior Sensitivity to Low Antigen Density Derived by Optimization of Co-Stimulation and CAR Architecture

Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only